Identifying risk factors for the prognosis of head and neck cutaneous squamous cell carcinoma: A systematic review and meta-analysis

Shihua Zeng, Lixin Fu, Peimei Zhou, Hua Ling

1 Department of Dermatology, Chengdu Second People’s Hospital, Chengdu, China, 2 Department of Anesthesiology, Chengdu Second People’s Hospital, Chengdu, China

☯ These authors contributed equally to this work.
* smartkiki2@126.com

Abstract

In this study, we sought to identify the potential impacts of disease characteristics on the prognosis of cutaneous squamous cell carcinoma (cSCC). We searched the PubMed, EmBase, and Cochrane Library databases from their inception until February 2020 to identify studies that investigated the prognosis of cSCC. The pooled effect estimates were applied using odds ratios (OR) and 95% confidence intervals (CI) and were calculated using the random-effects model. Forty-three studies including a total of 21,530 patients and reporting 28,627 cases of cSCC were selected for the final meta-analysis. Poor differentiation (OR, 3.54; 95% CI, 2.30–5.46; \( P < 0.001 \)), perineural invasion (OR, 3.27; 95% CI, 1.60–6.67; \( P = 0.001 \)), Breslow greater than 2 mm (OR, 5.47; 95% CI, 2.63–11.37; \( P < 0.001 \)), diameter greater than 20 mm (OR, 4.62; 95% CI, 2.95–7.23; \( P < 0.001 \)), and location on temple (OR, 3.20; 95% CI, 1.12–9.15; \( P = 0.030 \)) were associated with an increased risk of recurrence, whereas immunosuppression status and location on cheek, ear, or lip were not associated with the risk of recurrence. Poor differentiation (OR, 6.82; 95% CI, 4.66–9.99; \( P < 0.001 \)); perineural invasion (OR, 7.15; 95% CI, 4.73–10.83; \( P < 0.001 \)); Breslow greater than 2 mm (OR, 6.11; 95% CI, 4.05–9.21; \( P < 0.001 \)); diameter greater than 20 mm (OR, 5.01; 95% CI, 2.56–9.80; \( P < 0.001 \)); and location on temple (OR, 2.38; 95% CI, 1.39–4.09; \( P = 0.002 \)), lip (OR, 2.15; 95% CI, 1.26–3.68; \( P = 0.005 \)), and temple (OR, 2.77; 95% CI, 1.20–6.40; \( P = 0.017 \)) were associated with an increased risk of metastasis, whereas immunosuppression status and location on cheek did not affect the risk of metastasis. Finally, poor differentiation (OR, 5.97; 95% CI, 1.82–19.62; \( P = 0.003 \)), perineural invasion (OR, 6.64; 95% CI, 3.63–12.12; \( P < 0.001 \)), and Breslow greater than 2 mm (OR, 3.42; 95% CI, 1.76–6.66; \( P < 0.001 \)) were associated with an increased risk of disease-specific death, whereas diameter; immunosuppression status; and location on cheek, ear, lip, and temple did not affect the risk of disease-specific death. We found that differentiation, perineural invasion, depth, diameter, and location could affect the prognosis of cSCC. The potential role of other patient characteristics on the prognosis of cSCC should be identified in further large-scale prospective studies.
Introduction

Nonmelanoma skin cancer is the most common type of cancer, and the number of cases has increased to more than 1 million in the United States annually [1–3]. Cutaneous squamous cell carcinoma (cSCC) accounts for 20%–30% of nonmelanoma skin cancer, and most patients present with a head or neck location [4]. Most cases of cSCC can now be cured through surgery, but a certain subset of patients with high-risk cSCC could experience local recurrence, nodal metastasis, and disease-specific death (DSD) [5]. Although the prevalence of local recurrence, nodal metastasis, and DSD was low, the prognosis of these cases was poor, and the 5-year survival rate was only 30% to 60% for patients treated surgically for lymph node metastases from cSCC of head and neck [6].

The incidence of head and neck cSCC is increasing, and the specific anatomic subsites have been associated with an increased risk of regional metastatic involvement [7]. The parotid gland has been identified as a common location for spread because it could receive lymphatics from the ear, forehead, face, temple, and scalp [8]. Cancers with involvement of the parotid gland frequently demonstrated macroscopic or microscopic cervical metastases [9]. Other clinicopathological features, including differentiation, perineural invasion, depth, diameter, and immunosuppression, might also affect the prognosis of cSCC [10]. However, the predictive value of these clinicopathological features on the prognosis of cSCC vary. Therefore, the current systematic review and meta-analysis was conducted based on all available evidence to obtain pooled results regarding the predictive value of clinicopathological characteristics on the prognosis of cSCC.

Materials and methods

Data sources, search strategy, and selection criteria

This study was performed and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement [11]. Studies with an observational design that investigated the role of clinicopathological characteristics on the prognosis of cSCC were eligible for inclusion in this study, and restrictions were not applied for publication language or status (published, in press, or in progress). The electronic databases of PubMed, EmBase, and the Cochrane Library were systematically searched from their inception until February 2020 using the following search terms: (skin or cutaneous or dermal or cutanea) AND (squamous or epidermoid or planocellular or “prickle cell” or verrucous) AND (carcinoma) AND (outcome or recurrence or relapse or recrudescence or recurrent or recidive or metastatic or metastasis or spread or dissemination or secondary or migrant or death or morbidity or mortality or survival) AND (risk or risks or perineural invasion or “peri-neural invasion” or PNI or depth or thickness or size or diameter or or location or ear or ears or cheek or lip or lips or differentiation or immunocompromised or “immune compromised” or “sentinel lymph node”). Details regarding the search strategy are presented in S1 Appendix. The reference lists of retrieved studies were also reviewed manually to identify any additional studies that met the inclusion criteria.

Two reviewers independently conducted the literature search and study selection. Any disagreements were resolved by discussion until a consensus was reached. A study was included if it met all of inclusion criteria: (1) all patients had cSCC; (2) the study reported at least 1 of the following: differentiation, perineural invasion, depth, diameter, immunosuppression status, and location; and (3) the study reported at least 1 of the following: recurrence, metastasis, and DSD. Furthermore, there were no restrictions placed on study design.

Data collection and quality assessment

The information of included studies were collected by 2 reviewers independently. The abstracted items included the first author’s name, publication year, study design, country,
sample size, mean age, number of cSCCs, outcomes, risk factors, inclusion criteria, duration of follow-up, and investigated outcomes. The quality of included studies was assessed using the Newcastle-Ottawa Scale (NOS) according to selection (4 items, 4 stars), comparability (1 item, 2 stars), and outcome (3 items, 3 stars), and the “star system” for each individual study ranged from 0 to 9 [12]. The quality assessment was conducted by 2 reviewers, and any inconsistencies were resolved by an additional reviewer who referred to the full-text of the article.

Statistical analysis
The effect estimates for the role of clinicopathological characteristics on the prognosis of cSCC were assigned as odds ratios (OR) and 95% confidence intervals (CI), because the analysis included both prospective and retrospective studies. The random-effects model was applied to calculate the pooled effect estimates because it could consider the underlying variations across the included studies [13, 14]. I² and the Q statistic were applied to assess the heterogeneity among the included studies. Significant heterogeneity was defined as I² greater than 50.0% or a P value less than 0.10 [15, 16]. Sensitivity analysis was conducted for outcomes that reported 5 or more studies to assess the robustness of the pooled conclusions by sequential exclusion of individual studies [17]. Publication bias for outcomes that reported 5 or more studies was assessed using funnel plots, and the Egger and Begg tests [18, 19]. P values of less than 0.10 were considered as potential publication bias for the Egger and Begg tests. The inspection level for pooled results was 2-sided, and a P value less than 0.05 was regarded as statistically significant. All statistical analyses in this study were conducted using the STATA software (version 10.0; StataCorp, College Station, TX).

Results

Literature search
The electronic searches in PubMed, EmBase, and the Cochrane Library yielded 5946 articles, 2794 of which were retained after duplicate records were excluded. Of the remaining articles, 2711 were excluded because they reported irrelevant titles. The remaining 83 studies were retrieved for further full-text evaluation. Forty more studies were excluded for the following reasons: insufficient data (n = 18), other disease status (n = 13), and review or meta-analysis (n = 9). A total of 43 studies were selected for the final meta-analysis (Fig 1) [20–62]. Nineteen relevant studies were identified through reviewing the reference lists of the included studies. However, these studies were excluded as duplicate records because they had been included in the initial electronic searches.

Study characteristics
Table 1 summarizes the baseline characteristics of the included studies and patients. A total of 21,530 patients and 28,627 cSCCs were included. Seven studies were designed as prospective, and the remaining 36 studies were retrospective. Twenty-five studies were conducted in Europe, 17 studies were conducted in America, and 1 study was conducted in Asia. The sample size ranged from 41 to 6164, and the duration of follow-up ranged from 1.0 to 10.0 years. The quality of the studies was assessed using the NOS, and the number of NOS stars ranged from 5 to 9, with the median of 8 stars (interquartile range, 7–9 stars).

Recurrence
The summary results for the role of clinicopathological characteristics on the risk of recurrence for patients with cSCC are shown in Fig 2. The characteristics of poor differentiation (OR,
3.54; 95% CI, 2.30–5.46; P < 0.001) (Fig 2A), perineural invasion (OR, 3.27; 95% CI, 1.60–6.67; P = 0.001) (Fig 2B), Breslow greater than 2 mm (OR, 5.47; 95% CI, 2.63–11.37; P < 0.001) (Fig 2C), diameter greater than 20 mm (OR, 4.62; 95% CI, 2.95–7.23; P < 0.001) (Fig 2D), and location on temple (OR, 3.20; 95% CI, 1.12–9.15; P = 0.030) (Fig 2F) were associated with an increased risk of recurrence. However, immunosuppression status (OR, 1.94; 95% CI, 1.00–3.76; P = 0.050) (Fig 2E) and location on cheek (OR, 1.02; 95% CI, 0.68–1.53; P = 0.924) (Fig 2F), ear (OR, 1.30; 95% CI, 0.39–4.27; P = 0.668) (Fig 2F), or lip (OR, 0.82; 95% CI, 0.31–2.16; P = 0.686) (Fig 2F) did not affect the risk of recurrence in patients with cSCC. We noted significant heterogeneity for poor differentiation ($I^2 = 63.5\%; P = 0.001$), perineural invasion ($I^2 = 81.0\%; P < 0.001$), diameter greater than 20 mm ($I^2 = 68.2\%; P = 0.004$), and location on ear ($I^2 = 77.8\%; P = 0.004$). No significant heterogeneity was detected for Breslow greater than 2 mm ($I^2 = 0.0\%; P = 0.700$), immunosuppression status ($I^2 = 44.1\%; P = 0.111$), and location on lip ($I^2 = 0.0\%; P = 0.517$). Sensitivity analyses indicated that the pooled conclusions for poor differentiation, perineural invasion, diameter greater than 20 mm, and immunosuppression status were not altered by sequential exclusion of each individual study (S2 Appendix). Finally, there was no significant publication bias for the role of poor differentiation (Egger: $P = 0.585$; Begg: $P = 0.669$), perineural invasion (Egger: $P = 0.971$; Begg: $P = 0.386$), and diameter greater...
Table 1. Baseline characteristics of included studies and patients.

| Study               | Study design | Country | Sample size | Mean age (years) | No. Of cSCC | Outcomes                          | Risk factors                        | Inclusion criteria | Follow-up duration | NOS score |
|---------------------|--------------|---------|-------------|------------------|-------------|-----------------------------------|-------------------------------------|-------------------|-------------------|-----------|
| Immerman 1983 [20] | Retrospective | US      | 86          | NA               | 86          | Recurrence                        | Differentiation                    | Biopsy-proven cSCC | 4.5 years        | 9         |
| Goepfert 1984 [21] | Retrospective | US      | 520         | 64.0             | 967         | Recurrence, metastasis, disease-specific death | PNI                                | Biopsy-proven cSCC | 2.0 years        | 8         |
| Friedman 1985 [22] | Retrospective | US      | 63          | NA               | 71          | Recurrence, disease-specific death | Depth, differentiation             | Biopsy-proven cSCC | 8.0–18.0 years | 9         |
| Dinehart 1989 [23] | Retrospective | US      | 365         | 67.2             | 365         | Metastasis                        | Location                           | Biopsy-proven cSCC; treated with Mohs | 1.7 years        | 7         |
| Breuninger 1990 [24] | Retrospective | Germany | 571         | NA               | 673         | Metastasis                        | Location, diameter, differentiation, depth | Biopsy-proven cSCC | 6.0 years        | 8         |
| Stein 1994 [25]    | Retrospective | US      | 44          | 63.5             | 44          | Metastasis                        | Differentiation, depth             | Biopsy-proven cSCC of lip | 4.4 years        | 8         |
| Pereira 1994 [26]  | Retrospective | Portugal| 43          | NA               | 43          | Recurrence                        | Diameter                           | Biopsy-proven cSCC; treated with ED&C followed by cryotherapy | 4.0 years        | 5         |
| Eroğlu 1996 [27]   | Retrospective | Turkey  | 1,039       | 60.6             | 1,039       | Recurrence                        | Location, diameter, differentiation | Biopsy-proven cSCC | 2.3 years        | 8         |
| Baker 2001 [28]    | Retrospective | UK      | 183         | 78.0             | 227         | Regional metastasis               | Location                           | Biopsy-proven cSCC | 5.0 years        | 8         |
| Griffiths 2002 [29] | Retrospective | UK      | 157         | 73.7             | 157         | Metastasis                        | Location                           | Biopsy-proven cSCC | 5.0 years        | 9         |
| Cherpelis 2002 [30] | Retrospective | US      | 200         | NA               | 200         | Metastasis                        | Location, diameter, differentiation, PNI | Biopsy-proven cSCC; treated with Mohs | 0.5–10.0 years | 8         |
| Faustina 2004 [31] | Retrospective | US      | 111         | 64.0             | 111         | Metastasis                        | PNI                                | Biopsy-proven cSCC; periocular only | 6.4 years        | 6         |
| Mehrany 2005 [32]  | Retrospective | US      | 142         | 73.0             | 171         | Recurrence                        | Differentiation, immunosuppression | Biopsy-proven cSCC; treated with Mohs | 3.3 years        | 8         |
| Moore 2005 [33]    | Prospective   | US      | 193         | 68.0             | 193         | Metastasis                        | Location, differentiation, depth, PNI | Biopsy-proven head/neck cSCC | 1.7 years        | 6         |
| Clayman 2005 [34]  | Prospective   | US      | 210         | 67.1             | 277         | Disease-specific death            | Depth, PNI                         | Biopsy-proven cSCC | 1.8 years        | 8         |
| Lebovitch 2005 [35] | Prospective   | Australia | 1,177   | 64.0             | 1,177       | Recurrence                        | PNI                                | Biopsy-proven cSCC; treated with Mohs | 5.0 years        | 6         |
| Quaedvlieg 2006 [36] | Retrospective | Netherlands | 580   | 81.1             | 915         | Metastasis                        | Differentiation, PNI, depth         | Biopsy-proven cSCC | 5.7 years        | 7         |
| Mullen 2006 [37]   | Retrospective | US      | 136         | 67.0             | 149         | Recurrence                        | Diameter, differentiation           | Biopsy-proven cSCC | 2.4 years        | 9         |
| Harwood 2006 [38]  | Retrospective | UK      | 65          | 68.4             | 100         | Recurrence, metastasis            | Immunosuppression                   | Biopsy-proven primary cSCC; Immunocompromised group (OTR) with immunocompetent control group | 10.0 years        | 7         |
| Brantsch 2008 [39] | Prospective   | Germany | 615         | 73.0             | 615         | Recurrence, metastasis            | Depth, diameter, location, differentiation, immunosuppression | Biopsy-proven cSCC | 3.6 years        | 9         |
| Mourouzis 2009 [40] | Retrospective | UK      | 194         | 62.0–104.0       | 218         | Metastasis                        | Location, differentiation           | Biopsy-proven cSCC of the head and neck; treated with excision | 3.0 years        | 8         |

(Continued)
Table 1. (Continued)

| Study          | Study design | Country    | Sample size | Mean age (years) | No. Of cSCC | Outcomes                              | Risk factors                                     | Inclusion criteria                                      | Follow-up duration | NOS score |
|----------------|--------------|------------|-------------|------------------|-------------|---------------------------------------|---------------------------------------------------|----------------------------------------------------------|-------------------|-----------|
| Dorman 2010 [41] | Retrospective | UK         | 243         | 77.0             | 517         | Metastasis                            | Differentiation                                    | Biopsy-proven cSCC; extremities only                   | 6.2 years         | 7         |
| Pugliano-Mauro 2010 [42] | Retrospective | US         | 215         | 70.6             | 260         | Metastasis                            | Location                                          | Biopsy-proven high risk cSCC, including recurrent tumors; treated with Mohs | 3.9 years         | 7         |
| Kyrgidis 2010 [43]  | Prospective  | Greece     | 315         | 71.9             | 315         | Disease-specific death                | Depth, differentiation, PNI                        | Biopsy-proven cSCC                                     | 3.9 years         | 9         |
| Brougham 2012 [44]  | Retrospective | New Zealand | 6,164       | 74.0             | 8,997       | Metastasis                            | Location, PNI, differentiation                      | Biopsy-proven cSCC                                     | 5.9 years         | 8         |
| Metchnikoff 2012 [45] | Retrospective | US         | 41          | 53.3             | 225         | Recurrence                            | Diameter, differentiation, PNI                      | Biopsy-proven cSCC in heart/lung transplant recipients | 1.3 years         | 8         |
| Peat 2012 [46]  | Retrospective | New Zealand | 170         | 76.0             | 170         | Metastasis                            | Differentiation, PNI                                | Biopsy-proven cSCC                                     | 5.0 years         | 9         |
| Toll 2012 [47]  | Retrospective | Spain      | 101         | 77.7             | 101         | Metastasis                            | Differentiation, PNI                                | Ipsa-proven cSCC; metastatic group vs Nonmetastatic control group | 2.0 years         | 9         |
| Schmults 2013 [48]  | Retrospective | US         | 985         | 71.0             | 1,832       | Recurrence, metastasis, disease-specific death | Location, PNI                                      | Biopsy-proven cSCC; excluded SCCIS, recurrent SCC      | 4.2 years         | 9         |
| Roozeboom 2013 [49]  | Retrospective | Netherlands | 224         | 72.0             | 224         | Recurrence, metastasis                | Location, depth, differentiation, PNI               | Biopsy-proven cSCC                                     | 3.6 years         | 8         |
| Karia 2014 [50]  | Retrospective | US         | 974         | 71.0             | 1,818       | Recurrence, metastasis, disease-specific death | Location, diameter, depth, differentiation, immunosuppression | Biopsy-proven cSCC; excluded SCCIS, recurrent SCC, eyelid/ anogenital SCC | 4.2 years         | 9         |
| Vasconcelos 2014 [51]  | Retrospective | Brazil     | 61          | 67.1             | 79          | Recurrence                            | Differentiation, PNI                                | Biopsy-proven cSCC of head/neck; treated surgically    | 5.0 years         | 9         |
| Gonzalez 2014 [52]  | Retrospective | Argentina  | 434         | 74.0             | 434         | Metastasis                            | Differentiation                                    | Biopsy-proven cSCC; treated with Mohs                  | 4.7 years         | 7         |
| Brinkman 2015 [53]  | Retrospective | Netherlands | 131         | 73.0             | 155         | Metastasis, disease-specific death    | Differentiation                                    | Biopsy-proven cSCC; treated with surgical excision     | 6.8 years         | 8         |
| Krediet 2015 [54]  | Retrospective | Germany    | 143         | 73.0             | 143         | Metastasis                            | Diameter, differentiation, immunosuppression        | Biopsy-proven cSCC treated with excision              | 2.0 years         | 8         |
| Wermker 2015 [55]  | Retrospective | Germany    | 353         | 78.4             | 353         | Metastasis                            | PNI, immunosuppression                             | Biopsy-proven cSCC of external ear; treated surgically | 3.6 years         | 8         |
| Manyam 2015 [56]  | Retrospective | US         | 59          | 72.0             | 59          | Recurrence                            | Differentiation, PNI, immunosuppression             | Biopsy-proven cSCC treated with surgery and radiation | 1.5 years         | 7         |
| Schmidt 2015 [57]  | Retrospective | Australia  | 113         | 74.0             | 113         | Disease-specific death                | Diameter, immunosuppression                         | Biopsy-proven cSCC                                    | 5.0 years         | 8         |
| Hasegawa 2015 [58]  | Retrospective | Japan      | 451         | 65.9             | 451         | Metastasis                            | Differentiation                                    | Biopsy-proven cSCC                                    | 5.0 years         | 9         |
| Haisma 2016 [59]  | Retrospective | Netherlands | 336         | 73.0             | 545         | Metastasis                            | Location, diameter, depth, differentiation, PNI, immunosuppression | Biopsy-proven cSCC                                    | 3.6 years         | 8         |
| Eigentler 2017 [60]  | Prospective  | Germany    | 1,434       | 78.0             | 2,149       | Disease-specific death                | Location, diameter, depth, differentiation, immunosuppression | Biopsy-proven cSCC                                    | 3.0 years         | 8         |
than 20 mm (Egger: $P = 0.279$; Begg: $P = 0.548$) on the risk of recurrence. However, we noted a potential significant publication bias for the role of immunosuppression status on the risk of recurrence (Egger: $P = 0.082$; Begg: $P = 0.260$) (S3 Appendix). However, the conclusion was not changed after adjustment for potential publication bias using the trim and fill method [63].

### Metastasis

The summary results for the role of clinicopathological characteristics on the risk of metastasis for patients with cSCC are shown in Fig 3. We noted poor differentiation (OR, 6.82; 95% CI, 4.66–9.99; $P < 0.001$) (Fig 3A), perineural invasion (OR, 7.15; 95% CI, 4.73–10.83; $P < 0.001$) (Fig 3B), Breslow greater than 2 mm (OR, 6.11; 95% CI, 4.05–9.21; $P < 0.001$) (Fig 3C), diameter greater than 20 mm (OR, 5.01; 95% CI, 2.56–9.80; $P < 0.001$) (Fig 3D), location on ear (OR, 2.38; 95% CI, 1.39–4.09; $P = 0.002$) (Fig 3F), location on lip (OR, 2.15; 95% CI, 1.26–3.68; $P = 0.005$) (Fig 3F), and location on temple (OR, 2.77; 95% CI, 1.20–6.40; $P = 0.017$) (Fig 3F) were associated with an increased risk of metastasis. Immunosuppression status (OR, 1.57; 95% CI, 1.00–2.48; $P = 0.051$) (Fig 3E) and location on cheek (OR, 1.40; 95% CI, 0.60–3.29; $P = 0.393$) were not associated with an increased risk of metastasis.

### Table 1. (Continued)

|Study| Study design| Country | Sample size | Mean age (years) | No. Of cSCC | Outcomes | Risk factors | Inclusion criteria | Follow-up duration | NOS score |
|-----|-------------|---------|-------------|-----------------|-------------|-----------|--------------|-------------------|------------------|----------|
| Genders 2018 [61]| Retrospective | Netherlands | 593 | NA | 593 | Metastasis | Diameter, depth, differentiation | Biopsy-proven cSCC | 4.0 years | 7 |
| Pyne 2019 [62]| Prospective | Australia | 1,296 | 71.5 | 1,296 | Recurrence | Differentiation | Biopsy-proven cSCC | 9.0 years | 9 |

https://doi.org/10.1371/journal.pone.0239586.t001

---

D. diameter >20 mm

E. immunosuppression status

F. location

Fig 2. Risk factors for recurrence in patients with cSCC.

https://doi.org/10.1371/journal.pone.0239586.g002

---
Identifying risk factors for the prognosis of cutaneous squamous cell carcinoma

**Disease-specific death**

The summary results for the role of clinicopathological characteristics on the risk of DSD for patients with cSCC are shown in Fig 4. The summary ORs indicated that poor differentiation (OR, 5.97; 95% CI, 1.82–19.62; \( P = 0.003 \) (Fig 4A)), perineural invasion (OR, 6.64; 95% CI, 3.63–12.12; \( P < 0.001 \) (Fig 4B)), and Breslow greater than 2 mm (OR, 3.42; 95% CI, 1.76–6.66; \( P < 0.001 \) (Fig 4C)) were associated with an increased risk of DSD. Diameter greater than 20 mm (OR, 3.16; 95% CI, 0.82–12.23; \( P = 0.095 \) (Fig 4C)), immunosuppression status (OR, 1.90; 95% CI, 0.77–4.66; \( P = 0.161 \) (Fig 4C)), location on ear (OR, 1.93; 95% CI, 0.81–4.57; \( P = 0.137 \) (Fig 4D)), location on lip (OR, 1.60; 95% CI, 0.42–6.08; \( P = 0.490 \) (Fig 4D)), and location on temple (OR, 1.80; 95% CI, 0.22–14.79; \( P = 0.584 \) (Fig 4D)) did not affect the risk of DSD. Moreover, there was potential significant heterogeneity for poor differentiation (\( I^2 = 85.5%; P < 0.001 \)), perineural invasion (\( I^2 = 56.2%; P = 0.058 \)), Breslow greater than 2 mm (\( I^2 = 56.2% \) did not affect the risk of DSD. Moreover, there was potential significant heterogeneity for poor differentiation (\( I^2 = 85.5%; P < 0.001 \)), perineural invasion (\( I^2 = 56.2%; P = 0.058 \)), Breslow greater than 2 mm (\( I^2 = 50.1%; P = 0.111 \), ear (\( I^2 = 39.9%; P = 0.092 \)), and temple (\( I^2 = 62.0%; P = 0.015 \), but no significant heterogeneity for Breslow greater than 2 mm (\( I^2 = 30.6%; P = 0.156 \), immunosuppression status (\( I^2 = 33.0%; P = 0.176 \)), and location on lip (\( I^2 = 33.5%; P = 0.150 \). The pooled conclusions were stable and not changed by sequential exclusion of individual studies (S2 Appendix). Finally, there was no significant publication bias for the role of poor differentiation (Egger: \( P = 0.475 \); Begg: \( P = 0.487 \)), perineural invasion (Egger: \( P = 0.104 \); Begg: \( P = 0.161 \)), Breslow greater than 2 mm (Egger: \( P = 0.696 \); Begg: \( P = 0.876 \)), and immunosuppression status (Egger: \( P = 0.309 \); Begg: \( P = 0.764 \). The potential significant publication bias for diameter greater than 20 mm (Egger: \( P = 0.002 \); Begg: \( P = 0.640 \) (S3 Appendix) and the conclusion were not changed after adjustment for potential publication bias using the trim and fill method [63].

---

Fig 3. Risk factors for metastasis in patients with cSCC.

https://doi.org/10.1371/journal.pone.0239586.g003

\( P = 0.435 \) (Fig 3F) were not associated with the risk of metastasis. Moreover, there was potential significant heterogeneity for poor differentiation (\( I^2 = 57.7%; P = 0.001 \)), perineural invasion (\( I^2 = 54.8%; P = 0.009 \)), diameter greater than 20 mm (\( I^2 = 90.4%; P < 0.001 \), and location on cheek (\( I^2 = 50.1%; P = 0.111 \)), ear (\( I^2 = 39.9%; P = 0.092 \)), and temple (\( I^2 = 62.0%; P = 0.015 \), but no significant heterogeneity for Breslow greater than 2 mm (\( I^2 = 30.6%; P = 0.156 \), immunosuppression status (\( I^2 = 33.0%; P = 0.176 \)), and location on lip (\( I^2 = 33.5%; P = 0.150 \). The pooled conclusions were stable and not changed by sequential exclusion of individual studies (S2 Appendix). Finally, there was no significant publication bias for the role of poor differentiation (Egger: \( P = 0.475 \); Begg: \( P = 0.487 \)), perineural invasion (Egger: \( P = 0.104 \); Begg: \( P = 0.161 \)), Breslow greater than 2 mm (Egger: \( P = 0.696 \); Begg: \( P = 0.876 \)), and immunosuppression status (Egger: \( P = 0.309 \); Begg: \( P = 0.764 \). The potential significant publication bias for diameter greater than 20 mm (Egger: \( P = 0.002 \); Begg: \( P = 0.640 \) (S3 Appendix) and the conclusion were not changed after adjustment for potential publication bias using the trim and fill method [63].
Discussion

The current study was based on observational studies and explored the role of clinicopathological characteristics on the risk of recurrence, metastasis, and DSD. This comprehensive quantitative study included 21,530 patients and 28,627 cSCC from 7 prospective and 36 retrospective studies with a wide range of patient characteristics. The findings of this study found that poor differentiation, perineural invasion, and Breslow greater than 2 mm were associated with an increased risk of recurrence, metastasis, and DSD. Moreover, diameter greater than 20 mm and location on the temple were associated with excess risk of recurrence and metastasis. Finally, location on the ear or lip was associated with an increased risk of metastasis. Previous systematic review and meta-analysis included 36 studies and reported that the risk of recurrence was significantly increased with Breslow greater than 2 mm, invasion beyond subcutaneous fat, Breslow greater than 6 mm, perineural invasion, and poor differentiation. Invasion beyond subcutaneous fat; Breslow greater than 2 mm; Breslow greater than 6 mm; diameter greater than 20 mm; poor differentiation; perineural invasion; location on temple, ear, and lip; and immunosuppression were associated with an increased risk of metastasis.

Fig 4. Risk factors for DSD in patients with cSCC.

https://doi.org/10.1371/journal.pone.0239586.g004

= 62.3%; P = 0.047), diameter greater than 20 mm (I² = 87.5%; P < 0.001), and immunosuppression status (I² = 54.4%; P = 0.111), but no significant heterogeneity for location on ear (I² = 0.0%; P = 0.646) or lip (I² = 14.0%; P = 0.281). Furthermore, the pooled conclusions for the role of poor differentiation and perineural invasion on the risk of DSD were robust and not altered by sequential exclusion of individual studies (S2 Appendix). Finally, no significant publication bias was detected for poor differentiation (Egger: P = 0.414; Begg: P = 1.000) or perineural invasion (Egger: P = 0.536; Begg: P = 0.462) (S3 Appendix).
Furthermore, diameter greater than 20 mm, poor differentiation, location on ear or lip, invasion beyond subcutaneous fat, and perineural invasion were associated with an excess risk of DSD [10]. However, the additional published articles should be entered into a meta-analysis to reevaluate the role of clinicopathological characteristics on the prognosis of cSCC. Therefore, we conducted this systematic review and meta-analysis to provide an accurate predictive value of clinicopathological characteristics on the prognosis of cSCC.

The potential role of clinicopathological characteristics on the risk of recurrence was consistent with that reported in a previous meta-analysis [10]. Nearly all of studies reported similar results or trends. Moreover, most identified prognostic factors for the risk of metastasis were similar to the previous study. However, immunosuppression status was associated with a nonsignificant risk of metastasis, which was not consistent with the previous study [10]. The potential reasons could be accurate follow-up of immunocompromised patients for early diagnosis of cSCC patients in tertiary care centers and that the number of high-risk cSCCs among immunocompromised and immunocompetent patients were not balanced, which could affect the prognosis of cSCC. Moreover, although the role of most disease characteristics on the risk of DSD were consistent with a previous meta-analysis, the role of diameter, location on ear, and location on lip on the risk of DSD were inconsistent with the previous study. The potential reason for this could be that the results of previous study for the role of diameter, location on ear, and location on lip on the risk of DSD were based on only a single study. These results vary, and further large-scale prospective studies are needed for verification.

Several advantages of this study should be highlighted. First, most of the included studies were of relative high quality, and the pooled conclusions were robust. Second, the large sample size allowed us to quantitatively assess the role of clinicopathological characteristics on the prognosis of cSCC. Thus, our findings are potentially more robust than are those of any individual study. Third, the analysis of this study provides comprehensive results regarding the role of differentiation, perineural invasion, depth, diameter, immunosuppression status, and location on the risk of recurrence, metastasis, and DSD.

Despite these advantages, however there are also limitations that should be acknowledged. Most of the included studies were retrospective in design, and selection or recall bias was inevitable. In addition, significant heterogeneity was detected for several of the investigated outcomes, which was not fully interpreted by sensitivity analyses. Third, most of the reported results were unadjusted data, and the results could be affected by the patient characteristics. Fourth, the role of clinicopathological characteristics on the risk of DSD was reported in a smaller number of studies, and the conclusions might vary. Also, publication bias was inevitable because of the analysis based on published articles. Finally, the analysis was based on the study level, and individual data were not available.

Conclusion

In conclusion, this study indicated that the risk of recurrence, metastasis, and DSD among cSCC patients are significantly increased when patients are characterized by poor differentiation, perineural invasion, and Breslow greater than 2 mm. Moreover, we noted that diameter greater than 20 mm and location on the temple were associated with an increased risk of recurrence and metastasis. Furthermore, location on the ear or lip could result in an excess risk of metastasis in patients with cSCC. The results of this study should be verified by further prospective cohort studies.

Supporting information

S1 Checklist.

(DOC)
Author Contributions

Conceptualization: Shihua Zeng.

Data curation: Shihua Zeng, Lixin Fu, Peimei Zhou.

Methodology: Hua Ling.

Resources: Shihua Zeng, Lixin Fu.

Writing – original draft: Shihua Zeng.

Writing – review & editing: Shihua Zeng.

References

1. Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet (London, England). 2010; 375 (9715):673–85. Epub 2010/02/23. https://doi.org/10.1016/S0140-6736(09)61196-X PMID: 20171403.

2. Porceddu SV, Veness MJ, Guminski A. Nonmelanoma Cutaneous Head and Neck Cancer and Merkel Cell Carcinoma: Current Concepts, Advances, and Controversies. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015; 33(29):3338–45. Epub 2015/09/10. https://doi.org/10.1200/JCO.2014.60.7333 PMID: 26351348.

3. Eisemann N, Jansen L, Castro FA, Chen T, Eberle A, Nennecke A, et al. Survival with nonmelanoma skin cancer in Germany. The British journal of dermatology. 2016; 174(4):778–85. Epub 2015/12/18. https://doi.org/10.1111/bjd.14352 PMID: 26676514.

4. Gurney B, Newlands C. Management of regional metastatic disease in head and neck cutaneous malignancy. 1. Cutaneous squamous cell carcinoma. Br J Oral Maxillofac Surg. 2014; 52(4):294–300. Epub 2014/02/25. https://doi.org/10.1016/j.bjoms.2014.01.015 PMID: 24559975.

5. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. Journal of the American Academy of Dermatology. 2013; 68(6):957–66. Epub 2013/02/05. https://doi.org/10.1016/j.jaad.2012.11.037 PMID: 23375456.

6. Givi B, Andersen PE, Diggs BS, Wax MK, Gross ND. Outcome of patients treated surgically for lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2011; 33(7):999–1004. Epub 2011/02/02. https://doi.org/10.1002/hed.21574 PMID: 21284049.

7. Ebrahimi A, Moncrieff MD, Clark JR, Shannon KF, Gao K, Milross CG, et al. Predicting the pattern of regional metastases from cutaneous squamous cell carcinoma of the head and neck based on location of the primary. Head Neck. 2010; 32(10):1288–94. Epub 2010/01/22. https://doi.org/10.1002/hed.21332 PMID: 20091686.

8. O'Brien CJ, McNeil EB, McMahon JD, Pathak I, Lauer CS. Incidence of cervical node involvement in metastatic cutaneous malignancy involving the parotid gland. Head Neck. 2001; 23(9):744–8. Epub 2001/08/16. https://doi.org/10.1002/hed.1106 PMID: 11505484.

9. Andrucho JL, Veness MJ, Morgan GJ, Gao K, Clifford A, Shannon KF, et al. Implications for clinical staging of metastatic cutaneous squamous carcinoma of the head and neck based on a multicenter study of treatment outcomes. Cancer. 2006; 106(5):1078–83. Epub 2006/01/31. https://doi.org/10.1002/cncr.21698 PMID: 16444748.

10. Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL. Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death: A Systematic Review and Meta-analysis. JAMA Dermatol. 2016; 152(4):419–28. Epub 2016/01/15. https://doi.org/10.1001/jamadermatol.2015.4994 PMID: 26762219; PubMed Central PMCID: PMC4833641.
11. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine. 2009; 6(7):e1000097. Epub 2009/07/22. https://doi.org/10.1371/journal.pmed.1000097 PMID: 19621072; PubMed Central PMCID: PMC2707599.

12. Wells G, Shea B, O'Connell J. The Newcastle-Ottawa Scale (NOS) for Assessing The Quality of Non-randomised Studies in Meta-analyses. Ottawa Health Research Institute Web site. 2014; 7.

13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials. 1986; 7(3):177–88. Epub 1986/09/01. https://doi.org/10.1016/0197-2456(86)90046-2 PMID: 3802833.

14. Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Medical decision making: an international journal of the Society for Medical Decision Making. 2005; 25(6):646–54. Epub 2005/11/12. https://doi.org/10.1177/0272989X05282643 PMID: 16282215.

15. Deeks JJ, Higgins JPT, Altman DG. Analysing Data and Undertaking Meta-Analyses. In: J.P. Higgins SG, editor. Cochrane Handbook for Systematic Reviews of Interventions2008. p. 243–96.

16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003; 327(7414):557–60. Epub 2003/09/06. https://doi.org/10.1136/bmj.327.7414.557 PMID: 12958120; PubMed Central PMCID: PMC192859.

17. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Technical Bulletin. 1999; 8(47).

18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997; 315(7109):629–34. Epub 1997/10/06. https://doi.org/10.1136/bmj.315.7109.629 PMID: 9310563; PubMed Central PMCID: PMC2127453.

19. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088–101. Epub 1994/12/01. PMID: 7786990.

20. Goepfert H, Dichtel WJ, Medina JE, Lindberg RD, Luna MD. Perineural invasion in squamous cell skin carcinoma of the head and neck. Am J Surg. 1984; 148(4):542–7. Epub 1984/10/01. https://doi.org/10.1016/0002-9610(84)90385-4 PMID: 6486325.

21. Friedman HJ, Cooper PH, Wanebo HJ. Prognostic and therapeutic use of microstaging of cutaneous squamous cell carcinoma of the trunk and extremities. Cancer. 1985; 56(5):1099–105. Epub 1985/09/01. https://doi.org/10.1002/1097-0142(19850901)56:5<1099::aid-cncr2820560524>3.0.co;2-r PMID: 4016700.

22. Dininhart SM, Pollack SV. Metastases from squamous cell carcinoma of the skin and lip. An analysis of twenty-seven cases. Journal of the American Academy of Dermatology. 1989; 21(2 Pt 1):241–8. Epub 1989/08/01. https://doi.org/10.1016/s0190-9610(89)70168-7 PMID: 2768574.

23. Eroglu A, Berberoglu U, Berreroogu S. Risk factors related to locoregional recurrence in squamous cell carcinoma of the skin. Journal of surgical oncology. 1996; 61(2):124–30. Epub 1996/02/01. https://doi.org/10.1002/(SICI)1099-0098(199602)61:2<124::AID-JSO6>3.0.CO;2-E PMID: 860543.

24. Baker NJ, Webb AA, Macpherson D. Surgical management of cutaneous squamous cell carcinoma of the head and neck. Br J Oral Maxillofac Surg. 2001; 39(2):87–90. Epub 2001/04/05. https://doi.org/10.1054/bjoms.2000.0584 PMID: 11286440.

25. Griffiths RW, Feeley K, Suvarna SK. Audit of clinical and histological prognostic factors in primary invasive squamous cell carcinoma of the skin: assessment in a minimum 5 year follow-up study after conventional excisional surgery. Br J Plast Surg. 2002; 55(4):287–92. Epub 2002/08/06. https://doi.org/10.1054/bjps.2002.3833 PMID: 12160533.

26. Cherpelis BS, Marcusen C, Lang PG. Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatologic surgery: official publication for American Society for Dermatologic Surgery [et al]. 2002; 28(3):268–73. Epub 2002/03/19. https://doi.org/10.1046/j.1524-4725.2002.01169.x PMID: 11896781.
31. Faustina M, Diba R, Ahmadi MA, Esmaeli B. Patterns of regional and distant metastasis in patients with eyelid and periorbital squamous cell carcinoma. Ophthalmology. 2004; 111(10):1930–2. Epub 2004/10/07. https://doi.org/10.1016/j.ophtha.2004.02.009 PMID: 15465559.

32. Mehrany K, Weening RH, Pittelkow MR, Roenigk RK, Otley CC. High recurrence rates of squamous cell carcinoma after Mohs' surgery in patients with chronic lymphocytic leukemia. Dermatologic surgery: official publication for American Society for Dermatologic Surgery [et al]. 2005; 31(1):38–42; discussion Epub 2005/02/22. https://doi.org/10.1111/j.1524-722X.2005.01006 PMID: 15720094.

33. Moore BA, Weber RS, Prieto V, El-Naggar A, Holsinger FC, Zhou X, et al. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. The Laryngoscope. 2005; 115(9):1561–7. Epub 2005/09/09. https://doi.org/10.1097/01.mlg.0000173202.56793.9f PMID: 16148695.

34. Clayman GL, Lee JJ, Holsinger FC, Zhou X, et al. Mortality risk from squamous cell skin cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(4):759–65. Epub 2005/02/01. https://doi.org/10.1200/JCO.2005.02.155 PMID: 15681519.

35. Mehrany K, Weenig RH, Pittelkow MR, Roenigk RK, Otley CC. High recurrence rates of squamous cell carcinoma after Mohs' surgery in patients with chronic lymphocytic leukemia. Dermatologic surgery: official publication for American Society for Dermatologic Surgery [et al]. 2005; 31(1):38–42; discussion Epub 2005/02/22. https://doi.org/10.1111/j.1524-722X.2005.01006 PMID: 15720094.

36. Quaedvlieg PJ, Creytens DH, Epping GG, Peutz-Kootstra CJ, Nieman FH, Thissen MR, et al. Histopathological characteristics of metastasizing squamous cell carcinoma of the skin and lips. Histopathology. 2006; 49(3):256–64. Epub 2006/08/22. https://doi.org/10.1111/j.1365-2559.2006.02472.x PMID: 16918972; PubMed Central PMCID: PMC1619204.

37. Mullen JT, Feng L, Xing Y, Mansfield PF, Gershenwald JE, Lee JE, et al. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Annals of surgical oncology. 2006; 13(7):902–9. Epub 2006/06/22. https://doi.org/10.1245/S0960-1408(06)00099-3 PMID: 16788750.

38. Harwood CA, Proby CM, McGregor JM, Sheaff MT, Leigh IM, Cerio R. Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case-control series. Journal of the American Academy of Dermatology. 2006; 54(2):290–300. Epub 2006/01/31. https://doi.org/10.1016/j.jaad.2005.03.048 PMID: 16021121.

39. Brantsch KD, Meisner C, Schonfisch B, Trilling B, Wehner-Caroli J, Rocken M, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. The Lancet Oncology. 2008; 9(8):713–20. Epub 2008/07/12. https://doi.org/10.1016/S1470-2045(08)70178-5 PMID: 18617440.

40. Mourouzis C, Boynton A, Grant J, Umar T, Wilson A, Macpheson D, et al. Cutaneous head and neck SCCs and risk of nodal metastasis—UK experience. J Craniomaxillofac Surg. 2009; 37(8):443–7. Epub 2009/08/29. https://doi.org/10.1016/j.jcms.2009.07.007 PMID: 19713116.

41. Dordal EL, Ridha H, Vesely MJ. Long-term outcome of squamous cell carcinoma of the upper and lower limbs. J Plast Reconstr Aesthet Surg. 2010; 63(10):1705–11. Epub 2009/11/03. https://doi.org/10.1016/j.bjps.2009.07.003 PMID: 19879200.

42. Pugliano-Mauro M, Goldman G. Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma. Dermatologic surgery: official publication for American Society for Dermatologic Surgery [et al]. 2010; 36(10):1544–53. Epub 2010/11/06. https://doi.org/10.1111/j.1524-4725.2010.01576.x PMID: 21053415.

43. Kyrgidis A, Tzellos TG, Kechagias N, Patrikiodou A, Xirou P, Kitikidou K, et al. Cutaneous squamous cell carcinoma (SCC) of the head and neck: risk factors of overall and recurrence-free survival. European journal of cancer (Oxford, England: 1990). 2010; 46(9):1563–72. Epub 2010/03/27. https://doi.org/10.1016/j.ejca.2010.02.046 PMID: 20338745.

44. Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. Journal of surgical oncology. 2012; 106(7):811–5. Epub 2012/05/18. https://doi.org/10.1002/jso.23155 PMID: 22592943.

45. Metchnikoff C, Multy T, Singer JP, Golden JA, Arron ST. The 7th edition AJCC staging system for cutaneous squamous cell carcinoma accurately predicts risk of recurrence for heart and lung transplant recipients. Journal of the American Academy of Dermatology. 2012; 67(5):829–35. Epub 2012/01/31. https://doi.org/10.1016/j.jaad.2012.01.010 PMID: 22285618; PubMed Central PMCID: PMC3345300.

46. Peat B, Insull P, Ayers R. Risk stratification for metastasis from cutaneous squamous cell carcinoma of the head and neck. ANZ J Surg. 2012; 82(4):230–3. Epub 2012/04/19. https://doi.org/10.1111/j.1445-2197.2011.05994.x PMID: 22510179.

47. Toll A, Gimeno-Beltran J, Ferrandiz-Pulido C, Masferrer E, Yebenes M, Jugcla A, et al. D2-40 immuno-histochemical overexpression in cutaneous squamous cell carcinomas: a marker of metastatic risk.
Journal of the American Academy of Dermatology. 2012; 67(6):1310–8. Epub 2012/04/24. https://doi.org/10.1016/j.jaad.2012.03.007 PMID: 22521203.

48. Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol. 2013; 149(5):541–7. Epub 2013/05/17. https://doi.org/10.1001/jamadermatol.2013.2139 PMID: 23677079.

49. Roozeboom MH, Lohman BG, Westers-Attema A, Nelemans PJ, Botterweck AA, van Marion AM, et al. Clinical and histological prognostic factors for local recurrence and metastasis of cutaneous squamous cell carcinoma: analysis of a defined population. Acta dermato-venereologica. 2013; 93(4):417–21. Epub 2012/11/10. https://doi.org/10.2340/00015555-1501 PMID: 23138613.

50. Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Schmults CD. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. Journal of clinical oncology: official journal of the American Society for Clinical Oncology. 2014; 32(4):327–34. Epub 2013/12/25. https://doi.org/10.1200/JCO.2012.48.5326 PMID: 24366933; PubMed Central PMCID: PMC3897257 are found at the end of this article.

51. Vasconcelos L, Melo JC, Miot HA, Marques ME, Abbade LP. Invasive head and neck cutaneous squamous cell carcinoma: clinical and histopathological characteristics, frequency of local recurrence and metastasis. An Bras Dermatol. 2014; 89(4):562–8. Epub 2014/07/24. https://doi.org/10.1590/abd1808-4841.20142810 PMID: 25054741; PubMed Central PMCID: PMC4148268.

52. González A, Etchichury D, Creydt MP, Rivero M, Arizmendi CS. Abstracts of the XV World Congress on Cancers of the Skin, 3–6 September 2014. Edinburgh, Scotland. The British journal of dermatology. 2014; 171 Suppl 4(s4):1–76. Epub 2014/09/04. https://doi.org/10.1111/bjd.13282 PMID: 25182344.

53. Brinkman JN, Hajder E, van der Holt B, Van der Molen M, Huvisius SE, Mureau MA. The Effect of Differentiation Grade of Cutaneous Squamous Cell Carcinoma on Excision Margins, Local Recurrence, Metastasis, and Patient Survival: A Retrospective Follow-Up Study. Annals of plastic surgery. 2015; 75 (3):323–6. Epub 2014/01/10. https://doi.org/10.1097/SAP.0000000000000110 PMID: 24401812.

54. Krediet JT, Beyer M, Lenz K, Ulrich C, Lange-Aschenfeldt B, Stockfleth E, et al. Sentinel lymph node biopsy and risk factors for predicting metastasis in cutaneous squamous cell carcinoma. The British journal of dermatology. 2015; 172(4):1029–36. Epub 2014/11/05. https://doi.org/10.1111/bjd.13508 PMID: 25362868.

55. Wermker K, Kluwig J, Schipmann S, Klein M, Schulze HJ, Hallermann C. Prediction score for lymph node metastasis from cutaneous squamous cell carcinoma of the external ear. Eur J Surg Oncol. 2015; 41(1):128–35. Epub 2014/09/04. https://doi.org/10.1016/j.ejso.2014.07.039 PMID: 25182221.

56. Manyam BV, Gastman B, Zhang AY, Reddy CA, Burkey BB, Scharpf J, et al. Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy. Journal of the American Academy of Dermatology. 2015; 73 (2):221–7. Epub 2015/06/02. https://doi.org/10.1016/j.jaad.2015.04.037 PMID: 26028524.

57. Schmidt C, Martin JM, Khoo E, Plank A, Grigg R. Outcomes of nodal metastatic cutaneous squamous cell carcinoma of the head and neck treated in a regional center. Head Neck. 2015; 37(12):1808–15. Epub 2014/07/06. https://doi.org/10.1002/hed.23843 PMID: 24995842.

58. Hasegawa T, Tanakura M, Takeda D, Sakakibara A, Akashi M, Minamikawa T, et al. Risk factors associated with distant metastasis in patients with oral squamous cell carcinoma. Otolaryngol Head Neck Surg. 2015; 152(6):1053–60. Epub 2015/04/18. https://doi.org/10.1177/00015555-1501 PMID: 23138613.

59. Wermker K, Kluwig J, Schipmann S, Klein M, Schulze HJ, Hallermann C. Prediction score for lymph node metastasis from cutaneous squamous cell carcinoma of the external ear. Eur J Surg Oncol. 2015; 41(1):128–35. Epub 2014/09/04. https://doi.org/10.1016/j.ejso.2014.07.039 PMID: 25182221.

60. Manyam BV, Gastman B, Zhang AY, Reddy CA, Burkey BB, Scharpf J, et al. Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy. Journal of the American Academy of Dermatology. 2015; 73 (2):221–7. Epub 2015/06/02. https://doi.org/10.1016/j.jaad.2015.04.037 PMID: 26028524.

61. Haisma MS, Pialt BEC, Bijl HP, Roedenburg JLN, Diercks GFH, Romeijn TR, et al. Multivariate analysis of potential risk factors for lymph node metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. Journal of the American Academy of Dermatology. 2016; 75(4):722–30. Epub 2016/07/31. https://doi.org/10.1016/j.jaad.2016.06.010 PMID: 27473455.

62. Eigentler TK, Leiter U, Hafner HM, Garbe C, Rocken M, Breuninger H. Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. J Invest Dermatol. 2017; 137 (11):2309–15. Epub 2017/07/25. https://doi.org/10.1016/j.jid.2017.06.025 PMID: 28736229.

63. Genders RE, Osinga JA, Tromp EE, O’Rourke P, Bouwes Bavinck JN, Plasmeijer EI. Metastasis Risk of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients and Immunocompetent Patients. Acta dermato-venereologica. 2018; 98(6):551–5. Epub 2018/02/07. https://doi.org/10.2340/00015555-2901 PMID: 29405246.

64. Pyne JH, Myint E, Clark SP, Barr EM, Hou R. Early invasive squamous cell carcinoma recurrence rates: A study examining surgical margins, tumor surface diameter, invasion depth, and grade of differentiation in 1296 cases over 9 years. J Cutan Pathol. 2019; 46(2):111–6. Epub 2018/11/14. https://doi.org/10.1111/cup.13392 PMID: 30421922.
63. Duval S, Tweedie R. A Nonparametric “Trim and Fill” Method of Accounting for Publication Bias in Meta-Analysis. Journal of the American Statistical Association. 2000; 95(449):89–98. https://doi.org/10.1080/01621459.2000.10473905